Investigational drug · Phase 3
IMVT-1402
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
8
Any phase or sponsor naming "IMVT-1402"
First trial start
2024
Dec 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMVT-1402", any sponsor or status.
Conditions studied
As listed on its trial records.
- Graves' Disease
- Rheumatoid Arthritis
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
- Generalized Myasthenia Gravis
- Primary Sjögren's Syndrome
Approved drugs for the same conditions: Myasthenia gravis · Rheumatoid arthritis · Neurology · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "IMVT-1402" as an intervention, largest first.
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)Enrolling by invitation
Immunovant Sciences GmbHIndustry
NCT07286006 · 372 participants (planned) · Start Jan 26, 2026 · Primary completion Mar 2030
Drug: IMVT-1402 · For: Graves' Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Concord, California · 131 sites in all
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT06727604 · 240 participants (planned) · Start Dec 17, 2024 · Primary completion Jun 2028
Drug: IMVT-1402; IMVT-1402 and 1 more · For: Graves' Disease
Sites: Phoenix, Arizona; Huntington Beach, California; Los Angeles, California · 134 sites in all
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT07039916 · 231 participants (planned) · Start May 27, 2025 · Primary completion Dec 2027
Drug: IMVT-1402; IMVT-1402 and 2 more · For: Generalized Myasthenia Gravis
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 93 sites in all
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT07018323 · 210 participants (planned) · Start Jun 19, 2025 · Primary completion May 2027
Drug: IMVT-1402; IMVT-1402 and 1 more · For: Graves' Disease
Sites: Tucson, Arizona; Concord, California; Aurora, Colorado · 163 sites in all
- Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityPivotal-lookingActive, not recruiting
Immunovant Sciences GmbHIndustry
NCT06979531 · 180 participants (planned) · Start Jun 30, 2025 · Primary completion Jul 2028
Drug: IMVT-1402; Placebo · For: Primary Sjögren's Syndrome
Sites: Covina, California; El Cajon, California; Menifee, California · 96 sites in all
- Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT07032662 · 162 participants (planned) · Start Mar 18, 2025 · Primary completion Aug 2028
Drug: Imeroprubart; Placebo · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Tucson, Arizona; Carlsbad, California; Mission Hills, California · 143 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisPivotal-lookingActive, not recruiting
Immunovant Sciences GmbHIndustry
NCT06754462 · 120 participants (planned) · Start Jan 10, 2025 · Primary completion Sep 2027
Drug: IMVT-1402; Placebo · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Sun City, Arizona; Covina, California · 83 sites in all
- A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Active, not recruiting
Immunovant Sciences GmbHIndustry
NCT06980805 · 56 participants (planned) · Start Feb 19, 2025 · Primary completion Oct 2026
Drug: IMVT-1402; Placebo · For: Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 86 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New horizons for autoimmune hyperthyroidism with FcRn blockers.
Middleton F, Abraham P · Curr Opin Endocrinol Diabetes Obes 2026
- Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.
Liang P, Cai S, Sun W, et al. · Inflamm Res 2026
Also in development for Graves' Disease
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- BHV-1300Phase 32 trials
Biohaven Therapeutics Ltd. · Graves Disease, Graves' Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.